SS Innovations International Inc. (NASDAQ: SSII) is positioning itself at the forefront of telerobotic surgery, a field that is moving from isolated demonstrations toward broader clinical and regulatory development. A recent MedTech Dive report examined the technology's progress and the regulatory and infrastructure questions surrounding remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers.
According to the report, SS Innovations CEO Dr. Sudhir Srivastava emphasized that robotic surgery is inherently a form of teleoperation, and the central technical question is how much distance can be introduced without compromising responsiveness. This insight underscores the company's focus on pushing the boundaries of remote surgery.
As of September 28, 2026, SS Innovations reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad.
The growing interest in telerobotic surgery is putting SS Innovations International (NASDAQ: SSII) and Dr. Srivastava in an increasingly relevant part of the surgical robotics market. The MedTech Dive article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. The article highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL). For SS Innovations, the discussion comes as its SSi Mantra system is accumulating experience in telesurgery while the company pursues U.S. FDA clearance and European Union CE marking to expand into additional international markets.
The implications of this announcement are significant. Telerobotic surgery has the potential to revolutionize healthcare delivery by enabling expert surgeons to perform procedures remotely, improving access to specialized care in underserved regions. SS Innovations' progress in accumulating telesurgery experience and expanding its global footprint positions it as a key player in this emerging field. As regulatory approvals in the U.S. and Europe are sought, the company could further accelerate adoption and set standards for remote surgical care.
Investors and industry observers can follow SS Innovations' latest news and updates in the company's newsroom at https://ibn.fm/SSII. The company's advancements are closely monitored through platforms like MissionIR, which provides syndicated content to enhance visibility within the investment community. MissionIR is part of the Dynamic Brand Portfolio at IBN, delivering access to a vast network of wire solutions via InvestorWire and other services.
As telerobotic surgery gains ground, SS Innovations' ability to navigate regulatory pathways and expand its installed base will be critical. The company's focus on remote procedures could lead to improved patient outcomes and broader access to advanced surgical care, making its progress a development worth watching.
